Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974357 | 0.92 | ALDH1A1 (0.44) | ALDH1A1POLBTP53ALOX15PTPN1 | |
| SCHEMBL974832 | 0.91 | TP53 (0.46) | ALDH1A1POLBTP53ALOX15PTPN1 | |
| SCHEMBL2499550 | 0.86 | CNR1 (0.40) | CNR1CNR2CHRNB2CHRNA4 | |
| SCHEMBL17204428 | 0.82 | ELANE (0.54) | ALDH1A1POLBTP53ALOX15PTPN1 | |
| SCHEMBL17463438 | 0.81 | LTA4H (0.52) | ALDH1A1TP53ALOX15ELANEMEN1 | |
| SCHEMBL13433985 | 0.79 | ALDH1A1 (0.43) | ALDH1A1POLBTP53ALOX15PTPN1 | |
| SCHEMBL7961663 | 0.78 | ALDH1A1 (0.41) | ALDH1A1POLBTP53ALOX15PTPN1 | |
| SCHEMBL9699112 | 0.78 | NR5A1 (0.58) | TP53ALOX15CNR1CNR2 | |
| SCHEMBL17203742 | 0.78 | ALDH1A1 (0.41) | ALDH1A1POLBTP53ALOX15PTPN1 | |
| SCHEMBL9774077 | 0.78 | ALDH1A1 (0.50) | ALDH1A1POLBPTPN1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426433-B2 | Anticoagulant compounds, pharmaceutical compositions on their basis to treat thrombotic conditions, and plasma-substituting solution to correct hypercoagulation defects of hemodilution | Obschestvo S Ogranichennoi Otvetsttvennoctiyu “Bionika” (RU) | 2013-04-23 | — | — | US | disclosed |
| US-20110003826-A1 | ANTICOAGULANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS TO TREAT THROMBOTIC CONDITIONS, AND PLASMA-SUBSTITUTING SOLUTION TO CORRECT HYPERCOAGULATION DEFECTS OF HEMODILUTION | Obschestvo S Organichennoi Otvetsttvennoctiyu "Bio (RU) | 2011-01-06 | — | — | US | disclosed |
| US-20100324058-A1 | THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | OBSCHESTVO S ORGANICHENNOI OTVETSTTVENNOCTIYOU "BIONIKA" (RU) | 2010-12-23 | — | — | US | disclosed |
| CN-101861304-A | Thrombin functional compounds and pharmaceutical compositions based thereon | BIONIKA | 2010-10-13 | — | — | CN | disclosed |
| EP-2178839-A2 | NEW ANTICOAGULANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS TO TREAT THROMBOTIC CONDITIONS, AND PLASMA-SUBSTITUTING SOLUTION TO CORRECT HYPERCOAGULATION DEFECTS OF HEMODILUTION | Obschestvo S Ogranichennoi Otvetsttvennoctiyu "Bionika" (RU) | 2010-04-28 | — | — | EP | disclosed |
| EP-2178838-A2 | NEW THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | Obschestvo S Ogranichennoi Otvetsttvennoctiyu "Bionika" (RU) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009002228-A2 | NEW THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | OBSCHESTVO S OGRANICHENNOI OTVETSTTVENNOCTIYU 'BIONIKA' (RU) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002229-A2 | NEW ANTICOAGULANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS TO TREAT THROMBOTIC CONDITIONS, AND PLASMA-SUBSTITUTING SOLUTION TO CORRECT HYPERCOAGULATION DEFECTS OF HEMODILUTION | OBSCHESTVO S OGRANICHENNOI OTVETSTTVENNOCTIYU 'BIONIKA' (RU) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324058-A1 | THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | F2, PLAT, SERPINC1 | ALDH1A1 4317/4885POLB 4347/4885TP53 2953/4885 |
| US-20110003826-A1 | ANTICOAGULANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS TO TREAT THROMBOTIC CONDITIONS, AND PLASMA-SUBSTITUTING SOLUTION TO CORRECT HYPERCOAGULATION DEFECTS OF HEMODILUTION | F2, PROC, PLG | ALDH1A1 3871/4885POLB 2252/4885TP53 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.